Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05086289 · ClinicalTrials.gov registry record · Phase 2
Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain
A Phase 2 study of Chronic Low Back Pain, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 159
- Enrollment target
- 20
- Study locations
NCT05086289: Completed Phase 2 study of Chronic Low Back Pain, sponsored by Eli Lilly and Company.
NCT05086289 is a Phase 2 study of Chronic Low Back Pain that has completed, run by Eli Lilly and Company. The registered enrollment target is 159 participants, below the 590-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05086289, a Phase 2 study of Chronic Low Back Pain, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 159 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
Primary Outcome
The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine. Posterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3526318
Study Locations (20)
Florida
- VIN-Julie Schwartzbard - Aventura
- Suncoast Research Group - Miami
- New Horizon Research Center - Miami
- Renstar Medical Research - Ocala
- Synexus Clinical Research US, Inc - Orlando - Orlando
- Synexus Clinical Research US, Inc. - Pinellas Park
- Synexus Clinical Research US, Inc. - The Villages
Arizona
- Synexus- Chandler - Chandler
- Synexus Clinical Research - Glendale - Glendale
- Alliance for Multispecialty Research, LLC Tempe - Tempe
Massachusetts
- Boston Clinical Trials - Boston
- ActivMed Practices and Research - Methuen
- MedVadis Research Corporation - Waltham
California
- Artemis Institute for Clinical Research - Riverside
- Artemis Institute for Clinical Research - San Diego
Illinois
- Synexus Clinical Research US, Inc. - Chicago
- Northwestern University - Chicago
Connecticut
- CMR of Greater New Haven - Hamden
Idaho
- Rocky Mountain Clinical Research - Idaho Falls
Michigan
- Great Lakes Research Group, Inc. - Bay City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2021-10-25 |
| Est. Completion | 2022-06-17 |
| Phase | Phase 2 |
What the finished NCT05086289 record still lists
NCT05086289 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, below the 590-participant average among 71 other Chronic Low Back Pain trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Chronic Low Back Pain appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05086289 names 20 study sites across 8 states, led by Florida, Arizona, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05086289 about?
NCT05086289 is a clinical study titled "Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Chronic Low Back Pain". The purpose of this study is to test whether LY3526318 is efficacious and safe in relieving chronic low back pain (CLBP). This trial is part of the chronic pain master protocol H0P-MC-CPMP (NCT05986292) which is a protocol to accelerate the development of new treatments for chronic pain.
What is the current status of trial NCT05086289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 159 participants. The study started on 2021-10-25. Estimated completion is 2022-06-17.
What conditions does trial NCT05086289 study?
This clinical trial studies the following conditions: Chronic Low Back Pain.
What interventions are being tested in trial NCT05086289?
The interventions under investigation include: Placebo (DRUG), LY3526318 (DRUG).
Who is sponsoring clinical trial NCT05086289?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05086289 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Low Back Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05086289's enrollment target sits among peer trials
159 21st of 71 higher than 51 of 71 other Chronic Low Back Pain trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Low Back Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression
RECRUITING · Phase 2
-
Modulation Effect of tACS on Chronic Low Back Pain
RECRUITING · Phase 2
-
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
RECRUITING · Phase 2
-
Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure
ACTIVE NOT RECRUITING · Phase 2
-
Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4)
COMPLETED · Phase 2
-
Chronic Low Back Pain Research Project
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI